The global Intratumoral Cancer Therapies market is expected to garner a market value of USD 212.96 Billion in 2023 and is expected to accumulate a market value of USD 552.36 Billion by registering a CAGR of 10% in the forecast period 2023 to 2033. The growth of the Intratumoral Cancer Therapies market can be attributed to favorable regulatory frameworks for cancer treatments. The market for Intratumoral Cancer Therapies registered a CAGR of 7% in the historical period 2017 to 2022.
Cancer is among the top causes of mortality worldwide, and its incidence is increasing at an alarming rate. As a result, healthcare experts are concentrating on the development of efficient treatment and diagnosis solutions in order to reduce the incidence level. Early detection improves treatment regimen success rates. As a consequence, healthcare institutions and industrial companies are pushing routine exams through different awareness efforts.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 212.96 Billion |
| Anticipated Forecast Value (2033) | USD 552.36 Billion |
| Projected Growth Rate (2023 to 2033) | 10% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Intratumoral Cancer Therapies reflected a value of 7% during the historical period, 2017 to 2022. National lockdown, government controls, and a spike in infection rates across countries all had a major financial impact on neurological clinics and hospitals. Several clinics and hospitals have seen a decrease in patient visits as a result of COVID-19, thereby minimizing client engagement.
Many cancer diagnoses have been pushed back as a result of the COVID-19 dilemma. There was a global shortage of medical treatment for disorders other than COVID-19, which has had a detrimental influence on the Intratumoral Cancer Therapies business. Also, the restricted availability of healthcare personnel throughout the world is another aspect that has a negative impact on the Intratumoral Cancer Therapies industry.
However, post the pandemic, the complication in various people have increased. People suffering from even stage 1 cancer faced complications as the effects of the virus affected the immune system gravely. This paced up the demand for cancer therapies and also made the companies expand the product portfolio to provide enhanced immunity to the patients.
Thus, the market for Intratumoral Cancer Therapies is expected to register a CAGR of 10% in the forecast period 2023 to 2033.
Increasing incidence of cancer to push the market growth
According to the Globocan 2020 fact sheet, an estimated 19,292,789 new cancer cases were diagnosed worldwide, with nearly 9,958,133 deaths due to cancers, globally. Additionally, according to estimates from the International Agency for Research on Cancer (IARC), by 2040, the global burden of cancers is expected to grow to 27.5 million new cancer cases and 16.3 million deaths worldwide. The increasing incidence of cancer across the globe has been rapidly adding to the growth in the field of cancer research.
In April 2020, the US FDA approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with triple-negative breast cancer. Furthermore, in May 2020, the US FDA approved Tabrecta (capmatinib) for the treatment of adult patients with non-small cell lung cancer (NSCLC), and it is the first FDA-approved targeted therapy to treat NSCLC with specific mutations. Thus, the high research activities related to targeted therapies against cancers are expected to grow over the forecast period.
Principal Consultant
Strict Regulations and Higher Costs to restrict Market Growth
Inadequate reimbursement regulations are predicted to restrain market expansion. In recent years, there have been several developments in the cancer therapy industry. However, most medical insurance companies do not cover procedures that use computer-aided detection (CAD). As a consequence, individuals choose traditional diagnostic methods such as biopsies, and pathology tests, or conventional imaging methods such as mammography and MRI treatments. Furthermore, the high cost of intratumoral cancer therapy is projected to stifle market expansion.
Increased government funding propelling the growth of Intratumoral Cancer Therapies in Europe
The European market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period. Europe is estimated to be the fastest-growing region over the forecast period due to an increase in research funding by government bodies to help combat the growing incidence of cancer cases across the region. In addition, the existence of major players promotes expansion in the United Kingdom. These firms' strategies include new releases and growth initiatives, which will continue to help overall expansion in Europe.
In addition to this, the European Union’s ‘Horizon Europe Mission on Cancer’ was launched in September 2021 to offer funds to a broad spectrum of activities that are intended to lower Europe’s cancer burden by accelerating research and innovation in cancer therapeutics. The mission is anticipated to help over 3 million cancer survivors by the year 2030.
High Concentration of Key Players shaping the landscape for Intratumoral Cancer Therapies in North America
North America is expected to increase its market share in the future, owing to the increased adoption of cancer therapy and the growing burden of cancers in the USA. According to the Globocan 2020 report, an estimated 2,281,658 new cancer cases were diagnosed in the USA in 2020, with nearly 612,390 deaths. In 2020, The most common cancers were breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) in the USA.
In terms of market share and revenue, the North American market is predicted to be the most lucrative market during the forecast period with a revenue share of 40%. One of the primary factors propelling the industry in the region is the presence of various biotechnology and medical device firms. North America is likely to maintain its lead during the projection period due to factors such as increased spending for Research and Development initiatives and widespread use of new technology.
The region's high concentration of important players, growing FDA approvals, strategic partnerships, and substantial expenditure in research & development activities are projected to enhance the market. For instance, in November 2020, Merck & Co. Inc entered into a definitive agreement to acquire Velosbio Inc., which is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1).
Thus, given the aforementioned factors, the cancer therapy market is expected to grow significantly over the forecast period in North America.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The superior efficiency of checkpoint inhibitors bolsters the growth
On the basis of technology, the checkpoint inhibitors segment is estimated to witness the highest CAGR. The high growth can be attributed to the benefits offered by this therapeutic drug. Furthermore, the increasing product approvals by the regulatory authorities are expected to contribute to the market's growth. For instance, in August 2021, FDA approved the Glaxosmithkline PD-1 checkpoint inhibitor Jemperli (dostarlimab) for adults with mismatch repair-deficient recurrent or advanced endometrial cancer. Jemperli is an anti-PD-1 antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2.
Increased incidence of lung cancer to drive market growth
By application, lung cancer is estimated to account for the largest share of the market. Due to the increasing number of patients suffering from lung diseases, the lung cancer segment is expected to hold the largest share in the next ten years as well. Increasing incidences of lung cancer due to the rising smoking population is one of the major factors driving the growth of the lung cancer therapeutics market. The risk of lung cancer is tenfold higher in smokers as compared to non-smokers.
The market is being driven by a growing demand for tailored therapy, the availability of highly effective medications, an increase in the elderly population, and an increase in the prevalence of unhealthy lifestyles.
Key start-up players in the Intratumoral Cancer Therapies market are-
Key players in the Intratumoral Cancer Therapies market are Amgen Inc, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc, Novartis AG, Johnson & Johnson, and Eli Lily Company, F.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 212.96 Billion |
| Market Value in 2033 | USD 552.36 Billion |
| Growth Rate | CAGR of 10% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | End-Users, Application, Technology, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa (MEA) |
| Key Countries Profiled | USA, Canada, Brazil, Argentina, Germany, UK, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASIAN, GCC, South Africa |
| Key Companies Profiled | Amgen Inc; AstraZeneca; Bayer AG; Bristol-Myers Squibb Company; Pfizer Inc; Novartis AG; Johnson & Johnson; and Eli Lily Company; F. |
| Customization | Available Upon Request |
From 2017 to 2022, the Intratumoral Cancer Therapies market grew at a CAGR of 7%.
The global Intratumoral Cancer Therapies market is expected to grow with a 10% CAGR from 2023 to 2033.
As of 2033, the Intratumoral Cancer Therapies market is expected to reach USD 552.36 Billion
Checkpoint inhibitors segment is poised to register the highest growth rate through 2033
The Intratumoral Cancer Therapies market from the lung cancer application is predicted to observe the highest growth though 2033.
North America is expected to possess 40% market share for Intratumoral Cancer Therapies market in North America.
The European market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
1. Executive Summary | Intratumoral Cancer Therapies Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 5.1. Lung Cancer 5.2. Breast Cancer 5.3. Colorectal Cancer 5.4. Melanoma 5.5. Prostate Cancer 5.6. Head & Neck Cancer 5.7. Others 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technology Type 6.1. Monoclonal Antibodies 6.2. Vaccines 6.3. Checkpoint Inhibitors 6.4. Cell Therapies 6.5. Immune System Modulators 6.6. Adoptive Cell Transfer 6.7. Cytokines 6.8. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users 7.1. Hospital 7.2. Cancer Research Centres 7.3. Clinical 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. Asia Pacific 8.5. Middle East and Africa (MEA) 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Key Countries Market Analysis 15. Market Structure Analysis 16. Competition Analysis 16.1. Amgen Inc 16.2. AstraZeneca 16.3. Bayer AG 16.4. Bristol-Myers Squibb Company 16.5. Pfizer Inc 16.6. Novartis AG 16.7. Johnson & Johnson 16.8. Eli Lilly Company 16.9. F. Hoffmann-la Roche Ltd 16.10. Seattle Genetics Inc 17. Assumptions & Acronyms Used 18. Research Methodology
Explore Healthcare Insights
View Reports
Intratumoral Cancer Therapies Market
